2026–2029 positioned as the next strategic acquisition window
The features defining these billion-dollar transactions—mixmer chemistry, reliable delivery to heart and muscle, true systemic reach—are the key strengths of Elenae’s scalable platform.
Problem
Proven Markets, But Delivery Remains the Challenge
Despite proven success, today’s RNA medicine delivery platforms remain limited, complex, and costly.
✗ Multi-component (antibody + linker + oligo) = high COGS
✗ Complex biologics manufacturing
✗ Weak ASO chemistry (PMO)
✗ Receptor-dependent delivery
Elenae’s LNA mixmers deliver naked, in saline, to multiple organs—no formulation, no conjugate, no receptor dependency.
Platform
A Steric-Block Chemistry That Reaches Beyond the Liver
LNA ASO mixmers use a steric-blocking mechanism with no RISC loading and no RNase H cleavage. The ASO binds its target RNA through high-affinity LNA base-pairing and physically blocks biological processes without cutting the RNA.
Steric-Block Mechanism
No cleavage-associated toxicity. Enables exon skipping, splice modulation, miRNA inhibition, and translational regulation from a single chemistry.
Native Distribution
Heart, muscle, lung, retina, kidney, liver, and adipose reached after SC dosing in saline. No LNP, no GalNAc, no antibody conjugate required.
Chronic Safety
24-week NHP chronic dosing at 5 mg/kg/week SC. No hepatotoxicity, nephrotoxicity, immune activation, or injection site reactions across three species.
AI-Guided Design
Dual engines for miRNA targeting and exon skipping. 15 years of proprietary parameter libraries. Target-to-candidate in weeks. Iterative optimization from experimental data.
Tissue Distribution
Validated Multi-Organ Engagement
After a single subcutaneous dose of naked ASO in saline, LNA mixmers distribute broadly across major organs. Intrinsic to the chemistry, not engineered per-tissue. Compatible with conjugation strategies when tissue-restricted delivery is desired.
Heart
>95%
Mouse, Pig, NHP
Skeletal Muscle
>95%
Mouse, Pig, NHP
Lung
>95%
Mouse, NHP
Retina
Confirmed
Mouse, NHP
Kidney
>95%
Mouse, NHP
Liver
>95%
Mouse, NHP
Target engagement measured by miR-128-3p knockdown. Distribution intrinsic to LNA mixmer chemistry.
Near-complete miR-128 knockdown in liver, heart, lung, kidney, and muscle after single SC dose in saline. Includes LNA mixmer mechanism diagram (steric blocking of target RNA).
AI Design Engine
From Target to Optimized Lead in Weeks
Our proprietary computational engine screens millions of candidate sequences and predicts in vivo potency, toxicity liability, and tissue-specific pharmacology. 15 years of experimental data. Two modalities from one platform.
1
Target Input
miRNA target, mRNA splice site, or protein-coding exon. The engine accepts both modalities.
→
2
AI-Guided Design
Sequence optimization across potency, selectivity, toxicity, and tissue distribution parameters. Millions of candidates scored.
→
3
Optimized Leads
Validated candidates with in vitro dose-response and in vivo PK/PD. Picomolar IC50 leads from the first design cycle.
Intellectual Property
Elenae's platform is protected by a proprietary patent portfolio covering novel compositions, methods of treatment, and AI-guided design methodologies across multiple tissue types and therapeutic areas. IP details available under confidentiality agreement.
